Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study

20191,126 citationsJournal Article

Authors

Partnerships for the goals

Published in: The Lancet Oncology

Volume 20, Issue 9, pp. 1239-1251

Field-Weighted Citation Impact: 65.69